Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
KIR3DS1 Biologics Sequence Review Report 2026: Killer cell immunoglobulin-like receptor 3DS1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of KIR3DS1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KIR3DL3 Biologics Sequence Review Report 2026: Killer cell immunoglobulin-like receptor 3DL3 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of KIR3DL3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LAIR1 Biologics Sequence Review Report 2026: Leukocyte-associated immunoglobulin-like receptor 1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of LAIR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KIR3DL2 Biologics Sequence Review Report 2026: Killer cell immunoglobulin-like receptor 3DL2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of KIR3DL2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KIR2DS5 Biologics Sequence Review Report 2026: Killer cell immunoglobulin-like receptor 2DS5 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of KIR2DS5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KIR2DS4 Biologics Sequence Review Report 2026: Killer cell immunoglobulin-like receptor 2DS4 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of KIR2DS4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KIR3DL1 Biologics Sequence Review Report 2026: Killer cell immunoglobulin-like receptor 3DL1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of KIR3DL1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KIR2DS2 Biologics Sequence Review Report 2026: Killer cell immunoglobulin-like receptor 2DS2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of KIR2DS2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KIR2DS3 Biologics Sequence Review Report 2026: Killer cell immunoglobulin-like receptor 2DS3 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of KIR2DS3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KIR2DL5B Biologics Sequence Review Report 2026: Killer cell immunoglobulin-like receptor 2DL5B Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of KIR2DL5B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KIR2DS1 Biologics Sequence Review Report 2026: Killer cell immunoglobulin-like receptor 2DS1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of KIR2DS1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KIR2DL3 Biologics Sequence Review Report 2026: Killer cell immunoglobulin-like receptor 2DL3 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of KIR2DL3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.